3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
21
Phase 3
6
Phase 1
6
Phase NA
5
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
10
Breast Neoplasms
5
Sarcoma
2
Prostatic Neoplasms
2
Melanoma
2
Gastrointestinal Stromal Tumors
2
Urinary Bladder Neoplasms
1
Solitary Fibrous Tumors
1
Solid Tumors Refractory to Standard Therapy
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Osteosarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
Hemangioendothelioma
1
Fatigue
1
Colorectal Neoplasms
1
Chondrosarcoma, Extraskeletal Myxoid
1
Chondrosarcoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
6
aldesleukin
6
Cyclophosphamide
6
fludarabine phosphate
5
fludarabine
5
Nivolumab
4
durvalumab
3
Sorafenib
3
Radiotherapy
3
Filgrastim
3
Everolimus
3
Axitinib
3
Temozolomide
2
Peripheral Blood Stem Cell Transplantation
2
Isotretinoin
2
Ipilimumab
2
Interleukin-2
2
Interferon-alpha
2
Fluorouracil
2
Dexamethasone
2
Cyclosporine
2
Bevacizumab
2
vorolanib
1
tremelimumab
1
tocilizumab
1
talazoparib
1
spartalizumab
1
sargramostim
1
poly ICLC
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Kidney Neoplasms
×
Sunitinib
×
Clear all
NCT02446795
2017-01-18
QUASAR
Consorzio Oncotech
Phase 1/2
Unknown
104 enrolled